HiFiBiO Therapeutics

Thank you Spencer Huggett for showcasing our unique AI/ML-driven translational approach towards immunotherapy development!

We're so excited for #SITC2024! If you are also attending, don't forget to stop by our two posters showcasing our AI/ML clinical technology in two Phase 1 novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Learn more about these two programs and their therapeutic potential, even in IO refractory tumors! ? Can’t join in person? Our posters are now available on our website. https://lnkd.in/eJnxmUhw #cancer #aiandml #immunooncology #immunotherapy #innovation #DrugIntelligenceScience #TNFR2 #BTLA

We are thrilled to share that the FDA has cleared our IND application for HFB200604, our first inflammation and immunology program! ? HFB200604 is a best-in-class BTLA agonist monoclonal antibody developed using HiFiBiO’s proprietary Drug Intelligence Science (DIS?) platform. It is designed to restore immune tolerance in a host of autoimmune diseases by stimulating BTLA signaling in immune cells. https://lnkd.in/eSUKhF8P #autoimmune #inflammation #immunology #immunotherapy #innovation #BTLA #antibody #IND #agonist

Attending #SITC2024? Stop by our two posters showcasing our AI/ML clinical technology in two Phase 1 novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Learn more about these two programs and their therapeutic potential, even in IO refractory tumors! https://lnkd.in/eJnxmUhw ? #cancer #aiandml #immunooncology #immunotherapy #innovation #DrugIntelligenceScience #TNFR2 #BTLA

Come meet HiFiBiO's Timothy Miller at the upcoming #BIOEUROPE on November 4th to 6th in Stockholm, Sweden. Excited to connect and collaborate with fellow #biotech and #pharma leaders on partnership of our IO and I&I programs.?

HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #SITC2024 meeting, taking place Nov. 6-10 in Houston, Texas. The company will present Drug Intelligence Science (DIS?) enabled translational insights from ongoing Phase 1 clinical trials for its first-in-class TNFR2 agonist HFB200301 (NCT05238883) and best-in-class BTLA antagonist HFB200603 (NCT05789069).? ? Come visit our posters to learn how DIS? is uncovering deep translational insights to enhance clinical success! #cancer #aiandml #immunooncology #immunotherapy #innovation

Join HiFiBiO Therapeutics CEO Liang Schweizer at the Fierce 15 – Where are They Now? panel at the Fierce Biotech Summit 2024 in Boston on September 30 at 4:45pm EDT!?? ? We are excited to participate in the exciting discussions on the evolving biotech landscape and how leaders in the field are shaping the future of the industry. #biotech #innovation #leadership

Exciting news!?Join us at the #BiotechWeekBoston (BWB) Awards?next?Monday,?September 23,?where we’re honored to be?among the?finalists?for the?Start-up of the Year Award! We’re also thrilled to announce that?our CEO, Liang Schweizer, is named?a Finalist for the?prestigious?Lifetime Achievement Award.?? ? Under Liang’s?visionary?leadership, our passionate team has advanced a diverse portfolio of cutting-edge immunotherapies targeting cancers and autoimmune diseases, including three novel IO programs into Phase I. Furthermore, our single-cell and AI/ML powered Drug Intelligence Science (DIS?) translational platform represents a significant leap forward in precision medicine, allowing for more tailored therapies for individual patients and maximizing clinical success rates.? ? Click here to register for the event:?https://lnkd.in/ehi_EvwZ ? #biotech #immunotherapy #innovation #DrugIntelligenceScience #leadership?#BWB #StartupoftheYear #PrecisionMedicine #AI #CancerTherapies

Our team enjoyed the exciting conversations around our two posters at #ESMO2024! We were thrilled to share the promising Ph1 clinical trial results for HFB200301, a first-in-class TNFR2 agonist and HFB200603, a best-in-class BTLA antagonist in DIS(R)-selected solid tumors ? The full posters are up on our website for viewing: ? HFB200301: https://lnkd.in/eCA3uZnq HFB200603: https://lnkd.in/ebVAug3y

Reminder to stop by our two posters at #ESMO2024! HiFiBiO Therapeutics will present interim Phase 1 clinical data for two novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 and a best-in-class BTLA antagonist HFB200603.?These programs have shown promise both as monotherapy and in combination with anti-PD-1, demonstrating the capability to elicit a robust anti-cancer immune response, even in IO refractory tumors.? ? Link to press release and abstract: https://lnkd.in/eFgCHPxJ? ? #cancer #immunotherapy #innovation?